

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8349381

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DEFINED DIAGNOSTICS, LLC	11/08/2023
RECEIVING PARTY DATA	
Name:	PHARMA CINQ, LLC
Street Address:	1601 RESEARCH BOULEVARD
City:	ROCKVILLE
State/Country:	MARYLAND
Postal Code:	20850
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9213043
CORRESPONDENCE DATA	
Fax Number:	(703)712-8525
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-712-8531
Email:	gjoseph@medlerferro.com, docketing@medlerferro.com
Correspondent Name:	MEDLER FERRO WOODHOUSE & MILLS PLLC
Address Line 1:	8201 GREENSBORO DRIVE SUITE 1060
Address Line 4:	MCLEAN, VIRGINIA 22102
ATTORNEY DOCKET NUMBER:	0288-0059US1
NAME OF SUBMITTER:	CYNTHIA M. BOUCHEZ
SIGNATURE:	/CYNTHIA M. BOUCHEZ #47438/
DATE SIGNED:	12/26/2023
Total Attachments: 14	
source=PHARMACINQ- Intellectual Property Assignment#page1.tif	
source=PHARMACINQ- Intellectual Property Assignment#page2.tif	
source=PHARMACINQ- Intellectual Property Assignment#page3.tif	
source=PHARMACINQ- Intellectual Property Assignment#page4.tif	
source=PHARMACINQ- Intellectual Property Assignment#page5.tif	
source=PHARMACINQ- Intellectual Property Assignment#page6.tif	

source=PHARMACINQ- Intellectual Property Assignment#page7.tif
source=PHARMACINQ- Intellectual Property Assignment#page8.tif
source=PHARMACINQ- Intellectual Property Assignment#page9.tif
source=PHARMACINQ- Intellectual Property Assignment#page10.tif
source=PHARMACINQ- Intellectual Property Assignment#page11.tif
source=PHARMACINQ- Intellectual Property Assignment#page12.tif
source=PHARMACINQ- Intellectual Property Assignment#page13.tif
source=PHARMACINQ- Intellectual Property Assignment#page14.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (this “**IP Assignment**”), dated as of August 14, 2023, is executed and delivered by Samuel J. Wohlstadter (“**SJW**”), Nadine H. Wohlstadter (“**NHW**”), Wellstat ImmunoTherapeutics, LLC (“**ImmunoTherapeutics**”), Wellstat Ophthalmics Corporation (“**Ophthalmics**”), and Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC, “**Diagnostics**”), together with their respective successors and assigns (hereinafter collectively referred to as the “**Sellers**”), to Pharma Cinq, LLC, a Delaware limited liability company (“**Buyer**”). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Agreement (as hereinafter defined).

WHEREAS, under the terms of that certain Agreement (the “**Agreement**”), dated July 27, 2023, by and among SJW, NWH, Buyer and Madison VA Holdings, LLC, Sellers have agreed, among other things, to sell, convey, assign and transfer to Buyer certain assets of Sellers, which include certain intellectual property rights of Sellers, including the Assigned Patent Rights (as defined below) of Sellers;

WHEREAS, in connection with such sale, conveyance, assignment, and transfer of the Assigned Patent Rights, Sellers deliver this Patent Assignment for recording with the United States Patent and Trademark Office and corresponding entities or agencies in any applicable jurisdictions;

NOW THEREFORE, the parties agree as follows:

1. Assignment. For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Sellers hereby irrevocably sell, convey, assign and transfer to Buyer, and Buyer hereby accepts, all of Sellers’ right, title, and interest in and to the following, free and clear of all liens, claims, encumbrances and other interests, pursuant to the terms set forth in the Agreement:

(a) (i) all patents and patent applications (including provisional patent applications) in any jurisdiction, together with all divisionals, continuations, continuations-in-part, and international applications that claim priority to, or common priority with, the foregoing; (ii) all patents issuing therefrom (including utility models and design patents and certificates of invention); (iii) all reissues, reexaminations, inter partes reviews, renewals, restorations, extensions and supplementary protection certificates of any of the foregoing patent applications or patents; (iv) all confirmation patents, registration patents or patents of addition based on any of the foregoing patents; and (v) all foreign counterparts of any of the foregoing, or as applicable portions thereof (all of the foregoing items under clauses

(i) through (v), “**Patent Rights**”), in each case of clauses (i) through (v), that are owned by ImmunoTherapeutics, Ophthalmics, or Diagnostics, including without limitation the Patent Rights set forth on Schedule 1 hereto, together with the right to file applications and obtain Patent Rights;

(b) all rights of any kind whatsoever of Sellers accruing under any of the foregoing provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world (as all of the foregoing items under clauses (a) and (b), the “**Assigned Patent Rights**”); and

(c) all inventions, know-how, trade secrets, methods, procedures, and other technologies, whether or not patented or patentable, pertaining to the subject matter claimed in the Assigned Patent Rights (the “**Assigned Know-How**”)

2. Recordation and Further Actions. Sellers hereby authorize the Commissioner for Patents in the United States Patent and Trademark Office and the officials of corresponding entities or agencies in any applicable jurisdictions to record and register this Patent Assignment upon request by Buyer. As of and following the date hereof, and in accordance with the terms of the Agreement, Sellers shall promptly execute and deliver such documents as Buyer or its counsel may reasonably request, and take such further actions, to effectuate the purposes of this Patent Assignment, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documents, as may be reasonably necessary to effect, evidence or perfect the assignment of the Assigned Patent Rights to Buyer, or any assignee or successor thereto.

3. Terms of the Patent Assignment. This Patent Assignment, the Agreement and the schedules, annexes, and exhibits thereto, any other document required under the Agreement contain the entire understanding between and among the parties hereto with respect to the transactions contemplated by hereby and supersede and replace all prior and contemporaneous agreements and understandings, oral or written, with regard to such transactions. The Parties acknowledge and agree that this Patent Assignment is entered into pursuant to the Agreement, to which reference is made for a further statement of the rights and obligations of Sellers and Buyer with respect to the Assigned Patent Rights. Sellers and Buyer, by their execution of this Patent Assignment, hereby acknowledge and agree that neither the representations, warranties, covenants, agreements and indemnities, nor the rights and remedies of any party under the Agreement shall be deemed to be enlarged, decreased, modified, or altered in any way by this Patent Assignment. In the event of any inconsistencies or conflicts between this Patent Assignment and the Agreement, the terms of the Agreement shall govern.

4. Assignment. Buyer may freely transfer, assign or delegate this Patent Assignment, in whole or in part, without Sellers’ prior written consent.

5. Amendments; Waivers. This Patent Assignment may be amended or modified, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the parties hereto, or in the case of a waiver, by the party waiving compliance.

6. Counterparts. This Patent Assignment may be executed in counterparts, each of which shall be deemed to be an original, but all of which shall constitute same agreement. A signed copy of this Patent Assignment delivered by facsimile, e-mail, or other means of

electronic transmission shall be deemed to have the same legal effect as delivery of an original executed copy of this Patent Assignment.

7. Parties in Interest. This Patent Assignment shall inure to the benefit of and shall be binding upon the successors and permitted assigns of the parties hereto. Nothing in this Patent Assignment, express or implied, is intended to confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Patent Assignment except as expressly set forth herein.

8. Governing Law. This Patent Assignment shall be construed, performed and enforced in accordance with, and governed by, the Laws of the United States of America and the State of Delaware (without giving effect to the principles of conflicts of laws thereof), except to the extent that the Laws of such State are superseded by the Bankruptcy Code.

9. Severability. In the event that any part of this Patent Assignment is declared by any court or other judicial or administrative body to be null, void, or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Patent Assignment shall remain in full force and effect only if, after excluding the portion deemed to be unenforceable, the remaining terms shall provide for the consummation of the transactions contemplated hereby in substantially the same manner as originally set forth at the later of the date this Patent Assignment was executed or last amended.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Patent Assignment Agreement as of the date first above written.

SELLERS:

Samuel J. Wohlstadter

Samuel Wohlstadter

Nadine H. Wohlstadter

Nadine H Wohlstadter

WELLSTAT OPHTHALMICS CORPORATION

By: Samuel J. Wohlstadter
Name: Samuel J. Wohlstadter
Title: CEO

WELLSTAT IMMUNOTHERAPEUTICS, LLC Sen

By: Samuel J. Wohlstadter
Name: Samuel J. Wohlstadter
Title: managing director

DEFINED DIAGNOSTICS, LLC (f/k/a WELLSTAT DIAGNOSTICS, LLC)

By: Samuel J. Wohlstadter
Name: Samuel J. Wohlstadter
Title: Managing Director

Address for Notices:

Additional copy to Seller's counsel:

AGREED TO AND ACCEPTED:

BUYER:

Pharma Cinq, LLC
Delaware limited liability company

By: 

Name: Jacob Wohlstaedter

Title: President & CEO

Address for Notices:

1601 Research Boulevard
Rockville, Maryland 20850
Attention: Chief Executive Officer
Email: wohlstaedter@mesoscale.com

Additional copy by email to
legal@mesoscale.com

SCHEDULE 1
PATENT RIGHTS

Wellstat ImmunoTherapeutics, LLC

Patent No./ Appln. Publication No.	Application number	Title	Publication date
WO2012151468A1	US2012036459W	COMPLEMENT FACTOR B ANALOGS AND THEIR USES	2012-11-08
AU2012250614B2/ AU2012250614A1	AU2012250614A	Complement factor B analogs and their uses	2013-05-02
BR112013028271B1/ A2	BR112013028271A	análogos de fator b complementares e seus usos	2017-09-19
CA2833931C/ CA2833931A1	CA2833931A	COMPLEMENT FACTOR B ANALOGS AND THEIR USES	2012-11-08
CN103561765B/ CN103561765A	CN201280021957A	Complement factor B analogs and their uses	2014-02-05
EP2704744B1 EP2704744A4/A1	EP12779642A	COMPLEMENT FACTOR B ANALOGS AND THEIR USES	2019-04-24
DK2704744T3	DK12779642T	COMPLEMENT FACTOR B ANALOGS AND THEIR USES	2019-04-24
ES2738628T3	ES12779642T	Análogos del factor B del complemento y sus usos	2020-01-24
IL229243B	IL22924313A	Complement factor b analogs and their uses	2021-06-30
JP6162102B2 JP2014518621A	JP2014509468A	補体B因子アナログおよびその用途	2014-08-07
JP2017113035A	JP2017067501A	COMPLEMENT FACTOR B ANALOGS AND USES THEREOF	2017-06-29
KR101949293B1 KR20140047038A	KR20137028954A	COMPLEMENT FACTOR B ANALOGS AND THEIR USES	2019-02-18
MX350445B MX2013012791A	MX2013012791A	COMPLEMENT FACTOR B ANALOGS AND THEIR USES.	2014-04-14
NZ616479A	NZ61647912A	Complement factor b analogs and their uses	2016-01-29
RU2639521C2 RU2013153902A	RU2013153902A	ANALOGUES OF COMPLEMENT FACTOR B AND THEIR APPLICATION	2015-06-10

Patent No./ Appln. Publication No.	Application number	Title	Publication date
SG194780A1	SG2013081682A	COMPLEMENT FACTOR B ANALOGS AND THEIR USES	2013-12-30
US10415026B2 US2017037391A1	US201615334339A	Complement factor B analogs and their uses	2019-09-17
US10689637B2 US2019338268A1	US201916502623A	Complement factor B analogs and their uses	2020-06-23
US11001822B2 US2020325464A1	US202015931692A	Complement factor B analogs and their uses	2021-05-11
US9228003B2 US2014249072A1	US201214115115A	Complement factor B analogs and their uses	2016-01-05
US9533028B2 US2016082091A1	US201514951565A	Complement factor B analogs and their uses	2017-01-03
ZA201307589B	ZA201307589A	COMPLEMENT FACTOR B ANALOGS AND THEIR USES	2014-07-30
<u>WO 2018/209052</u>	PCT/US2018/032018	ENVELOPED VIRUS RESISTANT TO COMPLEMENT INACTIVATION FOR THE TREATMENT OF CANCER	2018-05-10
AU2018265258B2 AU2018265258A1	AU2018265258A	Enveloped virus resistant to complement inactivation for the treatment of cancer	2019-01-17
BR112018075281A2	BR112018075281A	vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer	2020-02-11
CA3026892A1	CA3026892A	ENVELOPED VIRUS RESISTANT TO COMPLEMENT INACTIVATION FOR THE TREATMENT OF CANCER	2018-11-15
CN109414483A	CN201880002553A	ENVELOPED VIRUS RESISTANT TO COMPLEMENT INACTIVATION FOR THE TREATMENT OF CANCER	2019-03-01
EP3621635A4 EP3621635A1	EP18798575A	ENVELOPED VIRUS RESISTANT TO COMPLEMENT INACTIVATION FOR THE TREATMENT OF CANCER	2021-02-24
IL263979B1 IL263979A	IL26397918A	Enveloped virus resistant to complement inactivation	2019-02-28
JP7161940B2 JP2020519230A	JP2018564966A	がんの治療のための、補体不活性化に 耐性のエンベロープウイルス	2020-07-02
KR20200005721A	KR20187037869A	암 치료용 보체 불활성화 내성의 외피 바이러스	2020-01-16

Patent No./ Appln. Publication No.	Application number	Title	Publication date
MX2018015599A	MX2018015599A	ENVELOPED VIRUS RESISTANT TO COMPLEMENT INACTIVATION FOR THE TREATMENT OF CANCER.	2019-05-16
RU2018146446A RU2018146446A3	RU2018146446A	ОБОЛОЧЕЧНЫЙ ВИРУС, РЕЗИСТЕНТНЫЙ К ИНАКТИВАЦИИ КОМПЛЕМЕНТОМ, ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ	2021-06-10
US11274141B2 US2019194292A1	US201816303729A	Enveloped virus resistant to complement inactivation for the treatment of cancer	2022-03-15
US2022169701A1 ABANDONED	US202217674990A	Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer	2022-06-02
ZA201808040B	ZA201808040A	ENVELOPED VIRUS RESISTANT TO COMPLEMENT INACTIVATION FOR THE TREATMENT OF CANCER	2019-09-25
WO2008106644A2	US2008055498W	TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION	2008-09-04
AU2008221287A1	AU2008221287A	Treatment of diseases characterized by inflammation	2008-09-04
AU2014203398A1	AU2014203398A	Treatment of diseases characterized by inflammation	2014-07-10
CA2678774A1	CA2678774A	TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION	2008-09-04
EP2134173A2/A4	EP08731123A	TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION	2009-12-23
JP5332064B2 JP2010520224A	JP2009551874A		2013-11-06 2010-06-10
KR20090122465A	KR20097020557A	TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION	2009-11-30
MX2009009200A	MX2009009200A	TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION	2009-10-28
NZ578873A	NZ57887308A	Complement factor B analogs and uses for the treatment of complement mediated disease such as inflammation	2012-01-12
US2010120665A1	US52917708A	TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION	2010-05-13

Wellstat Ophthalmics Corporation

Publication	Application number	Title	Publication date
WO2018071465A1	US2017056030W PCT/US17/056030	FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE	2018-04-19
AU2017344059B2/A1	AU2017344059A	Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide	2018-12-13
BR112018076674A2	BR112018076674A	proteína de fusão entre o fator de viabilidade do cone derivado de bastonetes de forma curta e um peptídeo hidrofílico	2019-04-02
CA3025977A1	CA3025977A	FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE	2018-04-19
CN109415423A	CN201780040158A	FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE	2019-03-01
EP3526238A1/A4	EP17860101A	FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE	2019-08-21
HK 40005252	HK19128633.5	FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE	2020-05-08
IL263990A	IL26399018A	Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide	2019-01-31
JP7028802B2 JP2019532616A	JP2018563544A	短鎖型桿体由来錐体生存因子及び親水性ペプチド間の融合タンパク質	2019-11-14
KR20190058388A	KR20187037891A	짧은 형태의 간상체 유래 원추체 생존능 인자와 친수성 펩타이드 사이의 융합 단백질	2019-05-29
MX2018015596A	MX2018015596A	FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE.	2019-03-14
RU2018144780A3 RU2018144780A	RU2018144780A	СЛИТЫЙ БЕЛОК КОРОТКОЙ ФОРМЫ ФАКТОРА ЖИЗНЕСПОСОБНОСТИ КОЛБОЧЕК, ПОЛУЧЕННОГО ИЗ ПАЛОЧЕК, И ГИДРОФИЛЬНОГО ПЕПТИДА	2020-11-17
US10946063B2 US2019151410A1	US201716301764A	Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide	2021-03-16

Publication	Application number	Title	Publication date
US2021162005A1	US202117172202A	Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide	2021-06-03
ZA201808041B	ZA201808041A	FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE	2019-09-25
WO2013063383A2	US2012062106W	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2013-05-02
AU2012321102C1/B2	AU2012321102A	Vectors encoding rod-derived cone viability factor	2013-05-16
BR112014010091A2	BR112014010091A	vetores codificando fator de viabilidade dos cones derivado dos bastonetes	2020-10-27
BR112014010091B1	BR112014010091A	ÁCIDO NUCLEICO, VETOR VIRAL, PREPARAÇÃO FARMACÊUTICA, USO DESTES, MÉTODO PARA PRODUÇÃO DE UMA PROTEÍNA RDCVF, E MÉTODO IN VITRO OU EX VIVO DE SECREÇÃO DE UMA PROTEÍNA RDCVF A PARTIR DE UMA CÉLULA	2022-11-08
CA2853379C CA2853379A1	CA2853379A	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2013-05-02
CN104321069A	CN201280064474A	Vectors encoding rod-derived cone viability factor	2015-01-28
CN110777124A	CN201911125836A	Vectors encoding rod-derived cone viability factor	2020-02-11
EP2797613B1 EP2797613A4/A2	EP12843778A	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2019-12-04
DK2797613T3	DK12843778T	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2019-12-04
ES2774779T3	ES12843778T	Vectores que codifican el factor de viabilidad de conos derivado de bastones	2020-07-22
HK1202049A1	HK15102471A	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2015-09-18
IN332848 (granted)	2916/DELNP/2014	VECTORS ENCODING ROD DERIVED CONE VIABILITY FACTOR	2020-02-28
JP6293664B2 JP2015501156A	JP2014539038A	桿体由来錐体生存因子をコードするベクター	2015-01-15
KR102000141B1 KR20140092320A	KR20147011857A	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2019-07-15

Publication	Application number	Title	Publication date
MX354516B MX2014004949A	MX2014004949A	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR.	2014-09-12
PL2797613T3	PL12843778T	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2020-06-15
RU2664673C2 RU2014121256A	RU2014121256A	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2015-12-10
US10040835B2 US2016108099A1	US201514962337A	Vectors encoding rod-derived cone viability factor	2018-08-07
US9265813B2 US2014328821A1	US201214354415A	VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR	2014-11-06

Defined Diagnostics Corp

Publication number	Application number	Title	Publication date
WO/2015/143277A1	US2015021678W	Antibodies and Methods for the Detection of Cell Death	2015-09-24
US2022065873A1 PENDING	US202117526941A	Antibodies and Methods for the Detection of Cell Death	2022-03-03
10401368 US20170192014	US201515127644A	Antibodies and Methods for the Detection of Cell Death	2019-09-03 2017-07-06
11,175,295 20200041526	16/514380	Antibodies and Methods for the Detection of Cell Death	2020-02-06 2021-11-16
EP3119805A1	EP15764318A	ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH	2017-01-25
WO2013071055A1	US2012064373W	ASSAY FOR DIABETES-ASSOCIATED AUTOANTIBODIES	2013-05-16
WO/2013/049509A1	US2012057826W	Assay panel for non-alcoholic steatohepatitis	2013-04-04
AU2012315784A1	AU2012315784A	Assay panel for non-alcoholic steatohepatitis	2013-05-16
WO/2012/154272	US2012026497W	Assays for detecting enzymatic activity	2012-11-15
AU2012254169A1 AU2012254169B2	AU2012254169A	Assays for detecting enzymatic activity	2013-05-16 2016-02-25
CA2864868A1	CA2864868A	Assays for detecting enzymatic activity	2012-11-15
EP2712423A1/A4	EP12781581A	Assays for detecting enzymatic activity	2014-04-02

Publication number	Application number	Title	Publication date
9244073 US2014141450	US201214117504A	Assays for detecting enzymatic activity	2016-01-26 2014-05-22
WO/2013/082463A2	US2012067353W	Assays, antibodies, immunogens and compositions related to 5-FU	2013-06-06
AU2012327223A1	AU2012327223A	Assays, antibodies, immunogens and compositions related to 5-FU	2013-06-20
CA2857645A1	CA2857645A	ASSAYS, ANTIBODIES, IMMUNOGENS AND COMPOSITIONS RELATED TO 5-FU	2013-06-06
US2015079612A1 US9702869B2	US201214361731A	Assays, Antibodies, Immunogens and Compositions Related to 5-FU	2015-03-19 2017-07-11
EP2785736A4/A2	EP12852770A	Assays, Antibodies, Immunogens and Compositions Related to 5-FU	2014-10-08
JP2015502356A	JP2014544935A	5-FUに関連するアッセイ、抗体、免疫原および組成物	2015-01-22
WO/2013/173525A1	US2013041255W	CLINICAL DIAGNOSTIC SYSTEMS	2013-11-21
AU2013262815A1 AU2013262815B2	AU2013262815A	Clinical diagnostic systems	2014-12-04 2016-06-23
AU2013262816A1 AU2013262816B2	AU2013262816A	Clinical diagnostic systems	2014-12-04 2016-06-23
CA2873459A1	CA2873459A	CLINICAL DIAGNOSTIC SYSTEMS	2013-11-21
CN104471384A	CN201380037617A	Clinical diagnostic systems	2015-03-25
US2015132861A1 US9625465B2	US201314401278A	CLINICAL DIAGNOSTIC SYSTEMS	2015-05-14 2017-04-18
EP2852834A4/A1	EP13790774A	CLINICAL DIAGNOSTIC SYSTEMS	2015-04-01
JP2015522801A	JP2015512815A	臨床診断システム Clinical diagnostic system	2015-08-06
WO/2013/173524A2	US2013041252W	CLINICAL DIAGNOSTIC SYSTEM INCLUDING INSTRUMENT AND CARTRIDGE	2013-11-21
US2015132860A1 US9213043B2	US201314401275A	CLINICAL DIAGNOSTIC SYSTEM INCLUDING INSTRUMENT AND CARTRIDGE	2015-05-14 2015-12-15
CA2873457A1	CA2873457A	CLINICAL DIAGNOSTIC SYSTEM INCLUDING INSTRUMENT AND CARTRIDGE	2013-11-21
CN104427929A	CN201380037637A	Clinical diagnostic system including instrument and cartridge	2015-03-18
EP2849632A2	EP13790062A	CLINICAL DIAGNOSTIC SYSTEM INCLUDING INSTRUMENT AND CARTRIDGE	2015-03-25
JP2015516583A	JP2015512814A	器具およびカートリッジを含む臨床診断システム Clinical diagnostic systems including instruments and cartridges	2015-06-11

Publication number	Application number	Title	Publication date
WO2016049148A1	US2015051665W	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF LYME DISEASE	2016-03-31
US11061028B2 US2018149648A1	US201515514264A	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF LYME DISEASE	2018-05-31 2021-07-13
WO2017007889A1	US2016041266W	COMPOUNDS AND METHODS FOR THE DETECTION OF METHOTREXATE	2017-01-12
US 11054430 B2 US20180328952 15/746404	US201615746404A	COMPOUNDS AND METHODS FOR THE DETECTION OF METHOTREXATE	2021-07-06 2018-11-15
WO/2014/131046A1	US2014018425W	ELECTROCHEMILUMINESCENCE (ECL) DETECTION REAGENTS AND RELATED METHODS FOR MEASURING ENZYME ACTIVITY	2014-08-28
AU2014218543A1	AU2014218543A	ELECTROCHEMILUMINESCENCE (ECL) DETECTION REAGENTS AND RELATED METHODS FOR MEASURING ENZYME ACTIVITY	2015-09-17
CA2901966A1	CA2901966A	ELECTROCHEMILUMINESCENCE (ECL) DETECTION REAGENTS AND RELATED METHODS FOR MEASURING ENZYME ACTIVITY	2014-08-28
CN105051536A	CN201480016789A	ELECTROCHEMILUMINESCENCE (ECL) DETECTION REAGENTS AND RELATED METHODS FOR MEASURING ENZYME ACTIVITY	2015-11-11
EP2959296A4/A1	EP14754657A	ELECTROCHEMILUMINESCENCE (ECL) DETECTION REAGENTS AND RELATED METHODS FOR MEASURING ENZYME ACTIVITY	2015-12-30
JP2016508727A	JP2015559284A	ELECTROCHEMILUMINESCENCE (ECL) DETECTION REAGENTS AND RELATED METHODS FOR MEASURING ENZYME ACTIVITY	2016-03-24
10125385 US20160002695	US201414770115A	ELECTROCHEMILUMINESCENCE (ECL) DETECTION REAGENTS AND RELATED METHODS FOR MEASURING ENZYME ACTIVITY	2018-11-13 2016-01-07
WO2013082273A1	US2012067041W	FILTRATION MODULE	2013-06-06
AU2012327218C1	AU2012327218A	FILTRATION MODULE	2015-12-24
EP2785429A4/A1	EP12852917A	FILTRATION MODULE	2014-10-08
10716887 US20180369473	US201816024889A	FILTRATION MODULE	2020-07-21 2018-12-27
10029041 US20140319079	US201214361733A	FILTRATION MODULE	2018-07-24 2014-10-30
D718462S	US201329469936F	Diagnostic instrument and sample cassette combination	2014-11-25

Publication number	Application number	Title	Publication date
D694422	US201229420965F	Diagnostic instrument and sample cassette combination	2013-11-26
CA148359S	CA148359F	Diagnostic instrument	2014-05-16
US20150266024	US201514732860A	Diagnostic systems and cartridges	2015-09-24
9075042	US201313844527A	Diagnostic systems and cartridges	2015-07-07
US20130337432			2013-12-19
9081001	US201313844450A	Diagnostic systems and instruments	2015-07-14
US20130315780			2013-11-28
AU347568S	AU201215575F	Sample cassette for a diagnostic instrument	2013-03-18
AU347304S	AU201310429F	Sample cassette for a diagnostic instrument	2013-02-26
AU347430S	AU201310427F	Sample cassette for a diagnostic instrument	2013-03-05
AU346947S	AU201215577F	Sample cassette for a diagnostic instrument	2013-02-14
AU347298S	AU201310408F	Sample cassette for a diagnostic instrument	2013-02-26
AU347296S	AU201310404F	Sample cassette for a diagnostic instrument	2013-02-26
AU347445S	AU201310431F	Sample cassette for a diagnostic instrument	2013-03-05
AU347444S	AU201310430F	Sample cassette for a diagnostic instrument	2013-03-05
BR302012005752S1	BR302012005752F	CONFIGURAÇÃO APLICADA A CASSETE DE AMOSTRA PARA INSTRUMENTOS DE DIAGNÓSTICO	2014-06-03
CA148360S	CA148360F	Sample cassette for a diagnostic instrument	2014-05-16
CA148281S	CA148281F	Sample cassette for a diagnostic instrument	2014-05-16
D700355	US201229420967F	Sample cassette for a diagnostic instrument	2014-02-25
D728122	US201329472941F	Sample cassette for a diagnostic instrument	2015-04-28
D718873	US201329473088F	Sample cassette for a diagnostic instrument	2014-12-02
D718872	US201329472908F	Sample cassette for a diagnostic instrument	2014-12-02
D697226	US201229420961F	Sample cassette for a diagnostic instrument	2014-01-07
AU346631S	AU201215541F	Medical diagnostic instrument with a display screen	2013-01-30
CA148275S	CA148275F	Diagnostic instrument with a display screen	2014-05-16
D728121	US201329470708F	Diagnostic instrument with a display screen	2015-04-28
D694899	US201229420956F	Diagnostic instrument with a display screen	2013-12-03